Key Points
Error: Response status code does not indicate success: 530 ().
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 50 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $495.01, for a total transaction of $24,750.50. Following the sale, the director owned 370 shares of the company's stock, valued at approximately $183,153.70. The trade was a 11.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Jan Malcolm also recently made the following trade(s):
- On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $512.12, for a total value of $25,606.00.
- On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $482.98, for a total value of $24,149.00.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $502.71 on Wednesday. The stock has a market capitalization of $21.65 billion, a PE ratio of 19.05, a P/E/G ratio of 4.71 and a beta of 0.84. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The business's fifty day moving average price is $481.47 and its 200-day moving average price is $398.76.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts' expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business posted $6.39 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms recently commented on UTHR. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a report on Thursday, October 30th. Wells Fargo & Company raised their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $509.50.
Check Out Our Latest Stock Report on United Therapeutics
Institutional Trading of United Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of United Therapeutics by 30.4% during the fourth quarter. GAMMA Investing LLC now owns 1,496 shares of the biotechnology company's stock worth $729,000 after purchasing an additional 349 shares in the last quarter. AIA Group Ltd bought a new stake in United Therapeutics during the third quarter valued at approximately $545,000. Allworth Financial LP lifted its position in United Therapeutics by 26.1% during the third quarter. Allworth Financial LP now owns 449 shares of the biotechnology company's stock valued at $188,000 after purchasing an additional 93 shares during the last quarter. Cambria Investment Management L.P. grew its stake in United Therapeutics by 20.9% in the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company's stock worth $1,114,000 after buying an additional 460 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of United Therapeutics by 66.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company's stock worth $299,000 after buying an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
